Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04696523 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage

Study acronym: Xe-SAH
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Notable Trial status: Not Yet Recruiting to Recruitingv6 Show 4 more changesShow less
    • Primary completion date: Dec 31, 2026 to Dec 31, 2029
    • Start date changed from estimate of Oct 1, 2023 to Apr 22, 2025
    • Study completion date: Dec 31, 2027 to Dec 31, 2029
    • Site details revised at 7 of 7 sites
  2. Notable Start date: Mar 1, 2023 to Oct 1, 2023v5
  3. Notable Primary completion date: Dec 31, 2025 to Dec 31, 2026
    • Start date: May 1, 2021 to Mar 1, 2023
    v4
  4. Notable Start date: Mar 1, 2021 to May 1, 2021v3
  5. Minor Study sites: 6 to 7
    • Secondary endpoints: details revised at 13 of 30 entries
    v2
  6. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
8,786 trials monitored
See 412 trials at risk
3,531 trials monitored
See 153 trials at risk
1,995 trials monitored
See 111 trials at risk
An investigator-initiated clinical drug study Main Objective: To explore neuroprotective properties of xenon in patients after aneurysmal subarachnoid hemorrhage (SAH). Primary endpoint: Global fractional anisotropy of white matter of diffusion tensor imaging (DTI). Hypothesis: White matter damage is less severe in xenon treated patients, i.e. global fractional anisotropy is significantly higher in the xenon group than in the control group as assessed with the 1st magnetic resonance imaging (MRI). After confirmation of aSAH and obtaining a signed assent subjects will be randomized to the following groups: Control group: Standard of Care (SOC) group: Air/oxygen and Normothermia 36.5-37.5°C; Xenon group: Normothermia 36.5-37.5°C +Xenon inhalation in air/oxygen for 24 hours. Brain magnetic resonance imaging techniques will be undertaken to evaluate the effects of the intervention on white and grey matter damage and neuronal loss. Neurological outcome will be evaluated at 3, 12 and 24 months after onset of aSAH symptoms Investigational drug/treatment, dose and mode of administration: 50±2 % end tidal concentration of inhaled xenon in oxygen/air. Comparative drug(s)/placebo/treatment, dose and mode of administration: Standard of care treatment according to local and international consensus reports. Duration of treatment: 24 hours Assessments: Baseline data Information that characterizes the participant's condition prior to initiation of experimental treatment is obtained as soon as is clinically reasonable. These include participant demographics, medical history, vital signs, oxygen saturation, and concentration of oxygen administered. Acute data The collected information will contain quantitative and qualitative data of aSAH patients, as recommended by recent recommendations of the working group on subject characteristics, and including all relevant Common Data Elements (CDE) can be applied. Specific definitions, measurements tools, and references regarding each SAH CDE can be found on the weblink here: https://www.commondataelements.ninds.nih.gov/SAH.aspx#tab=Data\_Standards.
Trial Details
NCT Number NCT04696523
Lead Sponsor Turku University Hospital
Collaborators: Academy of Finland
Conditions
(from sponsor)
Subarachnoid Hemorrhage, Aneurysmal, Cerebral Injury, Cerebral Ischemia, Cerebral Infarction, Cardiac Event, Cardiac Failure
Related terms Brain Injuries, Brain Ischemia, Cardiovascular Diseases, Cerebral Infarction, Heart Failure, Subarachnoid Hemorrhage
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov